Crinetics appoints Isabel Kalofonos as CCO ahead of paltusotine launch

Crinetics Pharmaceuticals, Inc.

Isabel Kalofonos named Chief Commercial Officer, effective Dec 16, 2024; leads paltusotine (once-daily SST2 agonist for acromegaly) launch prep and pipeline commercialization.
Compensation: $500k base salary, 40% target bonus; severance includes 9-month base pay (12-month + full target bonus if change in control within 12 months).
Expected Jan 10, 2025 grant of stock option for 100,000 shares; 25% vests Dec 16, 2025, remainder in 36 monthly installments.
Ms. Kalofonos previously CCO at Fulcrum Therapeutics; led ELAHERE launch at ImmunoGen and TAKHZYRO global launch at Takeda/Shire.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.